相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacogenetic Approach at the Serotonin Transporter Gene as a Method of Reducing the Severity of Alcohol Drinking
Bankole A. Johnson et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Interpretation of Subgroup Analyses in Randomized Trials: Heterogeneity Versus Secondary Interventions
Tyler J. VanderWeele et al.
ANNALS OF INTERNAL MEDICINE (2011)
Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer
Yoshinori Ito et al.
CANCER SCIENCE (2011)
Why, When, and How Should Pharmacogenetics Be Applied in Clinical Studies?: Current and Future Approaches to Study Designs
J. C. Stingl et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Pharmacogenetic Effect of the Stromelysin (MMP3) Polymorphism on Stroke Risk in Relation to Antihypertensive Treatment The Genetics of Hypertension Associated Treatment Study
Richard Sherva et al.
STROKE (2011)
What Is Clinical Utility and Why Should We Care?
L. J. Lesko et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials
Sue-Jane Wang et al.
CLINICAL TRIALS (2010)
Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Designing a Randomized Clinical Trial to Evaluate Personalized Medicine: A New Approach Based on Risk Prediction
Stuart G. Baker et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Confounding of Subgroup Analyses in Randomized Data
Rolf H. H. Groenwold et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
Steven M. Teutsch et al.
GENETICS IN MEDICINE (2009)
Comparison of the Pharmacokinetics of Venlafaxine Extended Release and Desvenlafaxine in Extensive and Poor Cytochrome P450 2D6 Metabolizers
Sheldon Preskorn et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2009)
When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D Study
Roy H. Perlis et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Pharmacogenetics-Tailoring Treatment for the Outliers
Janet Woodcock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies
Cristina Rodriguez-Antona et al.
PHARMACOGENOMICS (2009)
Pharmacogenomics of adverse drug reactions: practical applications and perspectives
Laurent Becquemont
PHARMACOGENOMICS (2009)
Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine
Felix W. Frueh
PHARMACOGENOMICS (2009)
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
Rianne M. F. van Schie et al.
PHARMACOGENOMICS (2009)
Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group
C. M. Bromley et al.
PHARMACOGENOMICS JOURNAL (2009)
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans
H. Schelleman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacogenetics: From bench to byte
J. J. Swen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Benefits and Risks of Drug Treatments How to Combine the Best Evidence on Benefits With the Best Data About Adverse Effects
Jan P. Vandenbroucke et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Pharmacogenomic biomarkers for prediction of severe adverse drug reactions
Magnus Ingelman-Sundberg
NEW ENGLAND JOURNAL OF MEDICINE (2008)
HLA-B*5701 screening for hypersensitivity to abacavir
Simon Mallal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Pharmacogenetic studies in depression: a proposal for methodologic guidelines
A. Serretti et al.
PHARMACOGENOMICS JOURNAL (2008)
Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors
Alfred O. Berg et al.
GENETICS IN MEDICINE (2007)
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
Jeffrey L. Anderson et al.
CIRCULATION (2007)
Low adoption of pharmacogenetic testing: an exploration and explanation of the reasons in Australia
David Corkindale et al.
PERSONALIZED MEDICINE (2007)
Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study
Hans Mulder et al.
ANNALS OF PHARMACOTHERAPY (2007)
Adaptive designs in clinical drug development - An Executive Summary of the PhRMA Working Group
Paul Gallo et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2006)
Pharmacogenetics-based therapeutic recommendations -: ready for clinical practice?
J Kirchheiner et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
A review on the design and reporting of studies on drug-gene interaction
KM Smits et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
What can mendelian randomisation tell us about modifiable behavioural and environmental exposures?
GD Smith et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
The epidemiologic approach to pharmacogenomics
J Little et al.
AMERICAN JOURNAL OF PHARMACOGENOMICS (2005)
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
P Wegman et al.
BREAST CANCER RESEARCH (2005)
Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation:: a randomized
JM Kemmeren et al.
BLOOD (2004)
Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?
M Zimmerman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Prospective GYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial
MP Murphy et al.
PHARMACOGENETICS (2000)
An ABC of drug-related problems
RHB Meyboom et al.
DRUG SAFETY (2000)
分享论文
